Ramei Sani-Grosso
Senior Vice President, Clinical Operations
Ramei has over 26 years of industry experience in pharmaceutical and biotech companies. She has held roles within Clinical Development as part of Clinical Science and Clinical Operations teams at companies such as Merck, Pfizer, GSK, Genentech, Onyx Pharmaceuticals, Inc. (now Amgen, Inc.), BioMarin, and BridgeBio. Ramei started her career at Merck & Co. and was involved in rotavirus vaccine development from bench to approval and label expansion of RotaTeq. While at BioMarin, Ramei was part of the team involved in the clinical development and submission of pegvaliase, which led to the approval of PALYNZIQ. For the past eight years Ramei has been part of companies focused on addressing orphan diseases in oncology and other rare genetic conditions. Prior to joining SonALAsense, Ramei served as Vice President of Clinical Operations at Calcilytix Therapeutics and Cantero Therapeutics (Bridgebio Pharma companies).
Ramei has over 26 years of industry experience in pharmaceutical and biotech companies. She has held roles within Clinical Development as part of Clinical Science and Clinical Operations teams at companies such as Merck, Pfizer, GSK, Genentech, Onyx Pharmaceuticals, Inc. (now Amgen, Inc.), BioMarin, and BridgeBio. Ramei started her career at Merck & Co. and was involved in rotavirus vaccine development from bench to approval and label expansion of RotaTeq. While at BioMarin, Ramei was part of the team involved in the clinical development and submission of pegvaliase, which led to the approval of PALYNZIQ. For the past eight years Ramei has been part of companies focused on addressing orphan diseases in oncology and other rare genetic conditions. Prior to joining SonALAsense, Ramei served as Vice President of Clinical Operations at Calcilytix Therapeutics and Cantero Therapeutics (Bridgebio Pharma companies).